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Available online 5 August 2016Background: The BASE ACS trial demonstrated an outcome of titanium–nitride–oxide-coated bioactive stents
(BAS) that was non-inferior to everolimus-eluting stents (EES) in patients presenting with acute coronary syn-
drome (ACS). We performed a post hoc analysis of elderly versus non-elderly patients from the BASE ACS trial.
Methods:We randomized 827 patients (1:1) presenting with ACS to receive either BAS or EES. The primary end-
point was major adverse cardiac events (MACE): a composite of cardiac death, non-fatal myocardial infarction
(MI), or ischemia-driven target lesion revascularization (TLR). Follow-up was planned at 12 months and yearly
thereafter for up to 7 years. Elderly age was deﬁned as ≥65 years.
Results: Of the 827 patients enrolled in the BASE ACS trial, 360 (43.5%) were elderly. Mean follow-up duration
was 4.2±1.9 years.MACEwasmore frequent in elderly versus younger patients (19.7% versus 12.0%, respective-
ly, p= 0.002), probably driven by more frequent cardiac death and non-fatal MI events (5.3% versus 1.5%, and
9.7% versus 4.5%, p = 0.002 and p = 0.003, respectively). The rates of ischemia-driven TLR were comparable
(p N 0.05). In propensity score-matched analysis (215 pairs), only cardiac deathwasmore frequent in elderly pa-
tients (6% versus 1.4%, respectively, p=0.01). Diabetes independently predicted bothMACE and cardiac death in
elderly patients.
Conclusions: Elderly patients treated with stent implantation for ACS had worse long-term clinical outcome,
compared with younger ones, mainly due to a higher death rate.
© 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.Keywords:
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With improved survival of the general population, more elderly pa-
tients are referred for percutaneous coronary intervention (PCI) with
stent implantation [1]. Elderly patients have higher-risk clinical and le-
sion characteristics and suffer more often short- and long-term adverse
outcome following PCI [2,3]. First-generation drug-eluting stents (DES)
improved the long-term efﬁcacy – and to a lesser extent the safety –
outcome of PCI, compared with bare-metal stents, in unselected elderlyentral Hospital, Sairaalantie 3,
inen).
cine. Published by Elsevier B.V. All rigpatients, and in elderly patients undergoing primary PCI for acute
ST-segment elevation myocardial infarction (MI) [3–5]. Implantation
of the second-generation everolimus-eluting stents (EES) in elderly pa-
tients was associated with a better mid-term angiographic and long-
term clinical outcome compared with paclitaxel-eluting stents, mainly
driven by a lower incidence of repeat revascularization [6,7].
The safety of titanium–nitride–oxide-coated bioactive stents (BAS)
was demonstrated in real-world unselected cohorts [8,9], and in ran-
domized controlled trials of patients presenting with acute coronary
syndrome (ACS) [10,11]. The adequately powered BASE ACS trial
showed non-inferiority of BAS versus EES, for the primary endpoint
of major adverse cardiac events (MACE) in patients with ACS, at
12-month, 2-year, and 4-year follow-up [11–13]. Yet, the comparative
outcome of BAS versus EES in elderly patients presenting with ACS ishts reserved.
Table 1
Baseline clinical, angiographic, and procedural characteristics of the 2 study groups.
Variable Elderly patients
N = 360
Non-elderly
patients
N = 467
p value
Age (years) 73.9 ± 6.2 54.6 ± 7.6 b0.001
Female gender 122 (33.9) 76 (16.3) b0.001
Current smoking 45 (12.5) 233 (49.9) b0.001
Hyperlipidemia 191 (53.1) 197 (42.2) 0.002
Hypertension 228 (63.3) 185 (39.6) b0.001
Family history of IHD 138 (38.3) 293 (51.2) b0.001
Presentation by STEMI 121 (33.6) 200 (42.8) 0.007
Prior MI 58 (16.1) 38 (8.1) b0.001
Prior PCI 43 (11.9) 40 (8.6) 0.10
Prior CABG 25 (6.9) 12 (2.6) 0.003
ACC/AHA lesion type B/C 321 (89.2) 410 (87.8) 0.54
Thrombus 135 (37.5) 229 (49) 0.001
Calciﬁed lesions 195 (54.2) 157 (33.6) b0.001
Bifurcation lesions 80 (22.2) 97 (20.8) 0.61
Reference vessel diameter (mm) 3.12 ± 0.43 3.15 ± 0.43 0.25
Lesion length (mm) 13.8 ± 6.4 14.8 ± 5.6 0.02
Stent diameter (mm) 3.12 ± 0.44 3.17 ± 0.44 0.16
Stent length (mm) 17.8 ± 5.4 18.6 ± 5.4 0.03
Total stent length per lesion (mm) 19.9 ± 8.8 21.2 ± 8.9 0.04
Number of vessels treated per patient 1.16 ± 0.43 1.13 ± 0.36 0.17
Number of lesions treated per patient 1.22 ± 0.53 1.17 ± 0.48 0.20
Direct stenting 90 (25) 170 (36.4) b0.001
Thrombus aspiration 45 (12.5) 109 (23.3) b0.001
Post-dilatation 155 (43.1) 202 (43.3) 0.95
Stent failure 2 (0.6) 3 (0.6) 1.00
Procedural success 360 (100) 465 (99.6) 0.50
Unfractionated heparin 72 (20) 143 (30.6) 0.001
Low-molecular-weight heparin 225 (62.5) 258 (55.2) 0.036
GP IIb/IIIa inhibitor 74 (20.6) 168 (36.0) b0.001
Bivalirudin 61 (16.9) 60 (12.8) 0.098
Continuous variables are presented as mean ± SD, whereas categorical variables are
presented as frequency (percentage).
BAS indicates bioactive stent; CABG, coronary artery bypass grafting; EES, everolimus-
eluting stent; GP, glycoprotein; MI, myocardial infarction; PCI, percutaneous coronary
revascularization.
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outcome of the BASE ACS trial in elderly patients (65 years or more),
with stent-based analysis of the outcome in the elderly and younger
subgroups.
2. Material and methods
2.1. Patient selection and study design
The trial design was previously described elsewhere [11]. In brief,
the BASE ACS trial was a prospective single-blinded multicentre ran-
domized controlled trial conducted in 14 centers. From January 2009
to September 2010, we randomized 827 patients (1:1) presenting
with ACS who underwent early PCI to receive either Titan-2® BAS
(Hexacath, Paris, France) or Xience V® EES (Abbott Vascular, Santa
Clara, California, USA). Follow-upwas planned at 12months, and yearly
thereafter for up to 7 years.
2.2. Ethical issues
The trial was initiated by the investigators and conducted according
to the ethical guidelines of the 1964 Declaration of Helsinki, as revised
in 2013. Informed written consent was obtained from every patient
after explanation of the trial protocol; the protocol was approved by
the ethics committees of the coordinating center (Satakunta Central
Hospital) and the other participating centers. The trial is registered
with ClinicalTrials.gov, number NCT00819923.
2.3. Pharmacological interventions
Patients not previously maintained on aspirin were pretreated with
aspirin at a loading dose of 250 mg orally or 250–500mg intravenously
and continued at a dose of 75–150 mg daily indeﬁnitely. Oral
clopidogrel was initiated at a loading dose of 300–600 mg before or im-
mediately after the procedure and continued at a dose of 75 mg daily.
Patients in either group were prescribed oral clopidogrel for a mini-
mum of 6 months, and thereafter, for extended periods (maximum
12 months) at the operator's discretion. During the procedure, low-
molecular-weight or unfractionated heparin was administered intra-
venously in the standard dosage. Use of glycoprotein IIb IIIa inhibitors
or bivalirudin was left to operator's discretion.
2.4. Deﬁnitions and study endpoints
Elderly patients were deﬁned as those having age of 65 years or
more. The diagnostic criteria for non-ST-segment elevation ACS and
ST-segment elevation MI were previously described [11]. The primary
endpoint was the ﬁrst occurrence of MACE: a composite of cardiac
death, non-fatal MI, or ischemia-driven target lesion revascularization
(TLR). Secondary endpoints included non-cardiac death and deﬁnite
stent thrombosis (ST). Cardiac death was deﬁned as death from cardio-
vascular causes or any death without known cause. ST was adjudicated
according to the criteria of deﬁnite ST described by the Academic
Research Consortium (ARC) [14]. An independent clinical events
committee whose members were blinded to stent group allocation ad-
judicated all the individual endpoints according to the prespeciﬁed
deﬁnitions.
2.5. Statistical analysis
Continuous variableswere presented asmean± standard deviation,
whereas categorical variables were describedwith absolute and relative
(percentage) frequencies. Comparisons between the two subgroups
(elderly versus younger) were performed using the unpaired t-test
for continuous variables, and the Pearson chi-square test or Fisher's
exact test for categorical variables, as appropriate. Data analysis wasbased on the intention-to-treat principle. We observed signiﬁcant dif-
ferences between the two subgroups in several baseline characteristics.
Therefore, we performed a propensity score-matched analysis of the
two subgroups. Propensity score was calculated using a logistic regres-
sion model in which we included clinical and procedural variables with
a difference between the two subgroups as indicated by a p b 0.1 in uni-
variate analysis. The stent types were included in the logistic regression
model as a dichotomous covariate in order to account for any possible
stent-related differences in outcome. Hosmer–Lemeshow test was
used to assess the ﬁt of the logistic regression model (chi-square: 7.37,
p = 0.497). Propensity score was employed for propensity score-
matched analysis to estimate the impact of age ≥ 65 years on the clinical
outcome.Matchingwas performed based on an estimated caliperwidth
of 0.2, the standard deviation of the propensity score logit. Comparisons
of clinical outcome were also performed based on the stent group
allocation within either subgroup individually (elderly and younger).
Time-to-event curves were constructed with the use of Kaplan–Meier
estimates, based on all the available follow-up data for MACE, and
were compared with the log-rank test. In order to identify the inde-
pendent predictors of outcome (MACE and cardiac death) within the
elderly subgroup, univariate analysis was initially performed for each
of the baseline clinical, angiographic, and procedural variables. Then,
the variables signiﬁcantly associated (2-sided p b 0.1) with the depen-
dent variable in univariate analysis were included as covariates in
a multivariable Cox regression hazard model in which the dependent
variable is the outcome variable (MACE or cardiac death). The results
of multivariable regression were presented as hazard ratio (HR) with
95% conﬁdence interval (CI). All tests were two-sided and statistical sig-
niﬁcance was set at 5%. Data were analyzed with SPSS version 16.
Table 2
Clinical outcome in the 2 study groups at long-term follow-up.
Elderly patients
N = 360
Non-elderly
patients
N = 467
HR (95% CI) p value
MACE 71 (19.7) 56 (12.0) 1.80 (1.23–2.64) 0.002
Cardiac death 19 (5.3) 7 (1.5) 3.66 (1.52–8.80) 0.002
Non-fatal MI 35 (9.7) 21 (4.5) 2.28 (1.30–4.0) 0.003
Ischemia-driven TLR 30 (8.3) 39 (8.4) 0.99 (0.60–1.64) 0.99
Non-cardiac death 29 (8.1) 8 (1.7) 5.02 (2.26–11.13) b0.001
Deﬁnite ST 11 (3.1) 7 (1.5) 2.07 (0.79–5.39) 0.12
Variables are presented as frequency (percentage).
BAS indicates bioactive stent; EES, everolimus-eluting stent; MACE, major adverse cardiac
events;MI,myocardial infarction; TLR, target lesion revascularization; ST, stent thrombosis;
HR, hazard ratio; CI, conﬁdence interval.
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3.1. Baseline clinical, angiographic, and procedural data
Of the 827 patients enrolled in the BASE ACS trial, 360 (43.5%)
were elderly (≥65 years). Median follow-up duration was 5.0 years;
mean (SD) 4.2 (1.9) years. Compared with younger patients, elderly
ones had a higher prevalence of female gender, were more likely
to be hypertensive and dyslipidemic, more likely to have prior coro-
nary events, and presented less often with ST-segment elevation MI
(p b 0.05 for all). They had more often calciﬁed but less often throm-
botic coronary lesions and had shorter lesion length (p b 0.05 for all).
They underwent more often predilation, but less often thrombus aspi-
ration, received shorter stents, and received less often glycoprotein IIb
IIIa inhibitors during the procedure (p b 0.05 for all). The baseline clin-
ical, angiographic, and procedural data are summarized in Table 1.
3.2. Long-term clinical outcome in crude population
The cumulative incidence ofMACE at long-term follow-upwasmore
frequent in elderly versus younger patients (19.7% versus 12.0%, respec-
tively, p=0.002) (Table 2 and Fig. 1). This was driven bymore frequent
cardiac death and non-fatalMI events (5.3% versus 1.5%, and 9.7% versus30
10
Log rank, p=0.001 20
Follow-up 
Number at risk
Elderly
Non-Elderly
360
467
307
433
290
421
261
373
MACE (%)
Fig. 1. Kaplan–Meier estimates of the primary endpoint (a composite of cardiac death, non-fa
subgroups at long-term follow-up. MACE indicates major adverse cardiac events.4.5%, p = 0.002 and p = 0.003, respectively). The rates of ischemia-
driven TLR and deﬁnite ST were comparable between the two sub-
groups (p N 0.05 both) (Table 2).3.3. Long-term clinical outcome in matched subgroups
Propensity score matching yielded 430 patients (215 pairs) with
balanced baseline characteristics (Table 3). In the propensity score-
matched pairs, the incidence of cardiac death was higher in elderly
versus younger patients (6% versus 1.4%, respectively, p= 0.01). Non-
cardiac death was also more frequent in the elderly (7.9% versus 2.3%,
respectively, p = 0.009). MACE and the other individual endpoints
were comparable between the two matched subgroups (p N 0.05
for all) (Table 4).3.4. Stent-based analysis of the two subgroups
In elderly patients, MACE was comparable between the two stent
arms (16.1% versus 23.3%, for BAS versus EES, respectively, p = 0.08).
Deﬁnite ST occurred less frequently with BAS versus EES (0.6% versus
5.6%, respectively, p = 0.006). The other individual endpoints were
comparable (p N 0.5 for all) (Fig. 2A). Comparably, in younger patients,
MACE and all the individual endpoints were comparable between the
two stent arms (p N 0.5 for all) (Fig. 2B).3.5. Analysis of adverse outcome in the elderly subgroup
In univariate analyses, the predictors of MACE in the elderly sub-
group were diabetes (p = 0.03), hypertension (p = 0.09), stent type
(p=0.08), and lesion calciﬁcation (p=0.08). Inmultivariable analysis,
the only independent predictor of MACE was diabetes (HR 1.67, 95% CI
0.99–2.80, p=0.051). Similarly, in univariate analyses, the predictors of
cardiac death in the elderly subgroup were diabetes (p= 0.01), hyper-
tension (p=0.05), and use of glycoprotein IIb IIIa inhibitor (p=0.09).
In multivariable analysis, the only independent predictor of cardiac
death was diabetes (HR 3.17, 95% CI 1.27–7.88, p= 0.013).19.7%
12%
Elderly
Non-elderly
(days)
246
362
208
251
64
70
18
22
tal myocardial infarction, or ischemia-driven target lesion revascularization) in the two
Table 3
Baseline clinical, angiographic, and procedural characteristics of the 2 matched-pairs
groups.
Variable Elderly patients
N = 215
Non-elderly
patients
N = 215
p value
Age (years) 73.1 ± 6.2 55.9 ± 7.3 b0.001
Female gender 53 (24.7) 51 (23.7) 0.82
Diabetes mellitus 42 (19.5) 41 (19.1) 0.90
Current smoking 44 (20.5) 37 (17.2) 0.38
Hyperlipidemia 115 (53.5) 103 (47.9) 0.24
Hypertension 116 (54.0) 108 (50.2) 0.44
Family history of IHD 103 (47.9) 95 (44.2) 0.43
Presentation by STEMI 78 (36.3) 78 (36.3) 1.00
Prior MI 33 (15.3) 26 (12.1) 0.32
Prior PCI 23 (10.7) 22 (10.2) 0.87
Prior CABG 15 (7.0) 11 (5.1) 0.41
ACC/AHA lesion type B/C 189 (87.9) 185 (86.0) 0.56
Thrombus 89 (41.4) 83 (38.6) 0.55
Calciﬁed lesions 94 (43.7) 88 (40.9) 0.55
Bifurcation lesions 49 (22.8) 41 (19.1) 0.34
Reference vessel diameter (mm) 3.13 ± 0.42 3.14 ± 0.43 0.90
Lesion length (mm) 14.2 ± 7.1 14.3 ± 5.1 0.87
Stent diameter (mm) 3.15 ± 0.43 3.15 ± 0.45 0.91
Stent length (mm) 18.0 ± 5.5 18.2 ± 5.3 0.67
Total stent length per lesion (mm) 20.2 ± 8.9 20.5 ± 7.9 0.71
Number of vessels treated per patient 1.17 ± 0.44 1.15 ± 0.41 0.65
Number of lesions treated per patient 1.23 ± 0.57 1.20 ± 0.55 0.54
Direct stenting 58 (27.0) 70 (32.6) 0.20
Thrombus aspiration 35 (16.3) 38 (17.7) 0.70
Post-dilatation 91 (42.3) 90 (41.9) 0.92
Stent failure 1 (0.5) 0 (0.0) 1.0
Procedural success 215 (100) 215 (100) NA
Unfractionated heparin 45 (20.9) 58 (27.0) 0.14
Low-molecular weight heparin 130 (60.5) 129 (60.0) 0.92
GP IIb/IIIa inhibitor 53 (24.7) 52 (24.2) 0.91
Bivalirudin 38 (17.7) 24 (11.2) 0.055
Continuous variables are presented as mean ± SD, whereas categorical variables are
presented as frequency (percentage).
BAS indicates bioactive stent; CABG, coronary artery bypass grafting; EES, everolimus-
eluting stent; GP, glycoprotein; MI, myocardial infarction; PCI, percutaneous coronary
revascularization.
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Fig. 2. Stent-based analyses of the 2 subgroups at long-term follow-up. BAS indicates
bioactive stents; EES, everolimus-eluting stents; MACE, major adverse cardiac events;
MI, myocardial infarction; ST, stent thrombosis; TLR, target lesion revascularization.
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4.1. Main ﬁndings
The current post hoc analysis of the BASE ACS trial demonstrated
that elderly patients presenting with ACS who were treated with early
PCI had worse long-term clinical outcome, compared with younger
ones, mainly due to a higher death rate. Diabetes independently pre-
dicted both MACE and cardiac death in such patient subgroup. More-
over, the long-term clinical outcome of BAS was comparable to that of
EES in the elderly, aswell as in the younger subgroup. The current report
is the ﬁrst to address the comparative outcome of BAS versus EES in
elderly patients with ACS.Table 4
Clinical outcome in the 2 matched-pairs groups at long-term follow-up.
Elderly patients
N = 215
Non-elderly
patients
N = 215
HR (95% CI) p value
MACE 39 (18.1) 27 (12.6) 1.54 (0.91–2.63) 0.10
Cardiac death 13 (6.0) 3 (1.4) 4.55 (1.28–16.19) 0.01
Non-fatal MI 18 (8.4) 12 (5.6) 1.55 (0.73–3.29) 0.25
Ischemia-driven TLR 15 (7.0) 18 (8.4) 0.82 (0.40–1.67) 0.58
Non-cardiac Death 17 (7.9) 5 (2.3) 3.61 (1.31–9.96) 0.009
Deﬁnite ST 5 (2.3) 4 (1.9) 1.26 (0.33–4.74) 1.00
Variables are presented as frequency (percentage).
BAS indicates bioactive stent; EES, everolimus-eluting stent; MACE, major adverse cardiac
events;MI,myocardial infarction; TLR, target lesion revascularization; ST, stent thrombosis;
HR, hazard ratio; CI, conﬁdence interval.4.2. Outcome of percutaneous coronary intervention in elderly patients
PCI is particularly challenging in elderly patients. In the current
report (43.5% elderly), the incidence of MACE was higher in elderly pa-
tients in the crude subgroup comparison. This is probably due to worse
baseline clinical and angiographic characteristics in the elderly, versus
younger, subgroup (Table 1); MACE rates were comparable in the
propensity-score-matched subgroups. Interestingly, both cardiac and
non-cardiac death rates were remarkably higher in the elderly sub-
group, even after propensity-score-matched analysis. Aligned with
this ﬁnding, prior studies consistently reported worse long-term mor-
tality rates in unselected elderly patients undergoing PCI, versus youn-
ger ones, using various age cutoff points. In 2 separate studies from
the bare-metal stents era, patients above 75 years had higher death
rates at 6-month and 3-year follow-up, compared with younger ones;
the difference was insigniﬁcant in the 6-month report due to the small
sample size; interestingly, repeat revascularization was similar in the
6-month report, and lower in the elderly in the 3-year report [15,16].
In another study, patients above 75 years had 91% survival at 12months
(no comparison group) [17]. Similarly, patients above 70 years had
lower event-free survival at 2-year follow-up, compared with younger
ones [18]. In another report of bare-metal stents, age independently
predicted late mortality; the 1-year death rate increased step-wise
with advancing age (3 age subgroups with cutoff at 70 and 80 years)
[19]. Likewise, in a large registry from the DES era (patients received
47W. Nammas et al. / European Journal of Internal Medicine 37 (2017) 43–48either ﬁrst-generation DES or bare-metal stents), the all-cause death
was higher in the oldest 2 quintiles, compared with the younger ones,
at 3-year follow-up [3]. Finally, death rates were higher in patients
above 70 years, versus younger ones, from pooled data of 5 prospective
trials of paclitaxel-eluting stents through 5 years of follow-up, aswell as
in 2 post-market registries of the same stent through 2 years: interest-
ingly, the rates of MI, ST, and TLR were comparable between the 2 age
groups in the trial data, and lower in elderly patients in the registry
data [20]. In the original report of the BASE ACS trial, age independently
predicted MACE at 12-month follow-up [11].
The mechanisms underlying increased cardiac mortality in the
elderly patients with ACS undergoing PCI are still unclear. In an early
pooled analysis of the PAMI trials (bare-metal stents), patients above
75 years had higher cardiac and non-cardiac in-hospital mortality;
age ≥ 75 years was an independent predictor of in-hospital mortality,
along with lower left ventricular ejection fraction, lower ﬁnal TIMI ﬂow,
higher Killip class, need for an intra-aortic balloon counterpulsation,
and post-MI stroke/transient ischemic attack, or signiﬁcant arrhythmia,
[21]. In post hoc analysis of the CADILLAC trial in patients with acute MI
undergoing primary PCI, 1-year mortality increased exponentially after
the age of 65 years, independent of the reperfusion modality or the
use of abciximab; both age and absent ST-segment resolution were in-
dependent predictors of 30-day MACE [22,23]. Yet, in patients with
ST-segment elevationMI treated by primary PCI, increasing age was as-
sociated with poor myocardial perfusion (as reﬂected by myocardial
blush grade 0–1 and ST-segment resolution b50%); both age and poor
myocardial perfusion were independent predictors of 1-year mortality
[24]. Comparably, in the current report, diabetes independently pre-
dicted both MACE and cardiac death in elderly patients at long-term
follow-up. Surrogates of myocardial perfusion were not investigated
in the current trial. Nevertheless, in a small study of patients undergo-
ing primary PCI for ST-segment elevation MI, diabetes was associated
with surrogates of poor myocardial perfusion in multivariable analysis
[25]. Finally, elderly patients have a higher risk of non-cardiac mortal-
ity, for instance, due to more deaths from cancer and lung diseases.
Investigation of these factors was out of scope of the current study.
In the current study, ischemia-driven TLR was comparable between
elderly and younger patients in the crude subgroup analysis and
remained so in the propensity-score-matched analysis (Tables 2 and 4);
this is consistent with data from the prior reports [15–17,19,20]. In
the elderly subgroup, TLR rates were comparable between the 2 stent
arms (Fig. 2A). Comparably, EES implantation in the elderly was associ-
atedwith lower rates of ischemia-driven TLR andMACE, comparedwith
paclitaxel-eluting stents, in pooled data from the SPIRIT III and SPIRIT IV
trials [6,7]. In turn, paclitaxel-eluting stent implantation in the elderly
was associated with lower rates of ischemic target vessel revasculariza-
tion, compared with bare-metal stents [5]. Similarly, in the current
report, deﬁnite ST was comparable between elderly and younger pa-
tients both in the crude and propensity-score-matched analyses
(Tables 2 and 4). This is consistent with pooled data from prior trials
through 5 years [20]. In the elderly subgroup, however, patients treated
with BAS, versus EES, had a signiﬁcantly lower rate of deﬁnite ST at
long-term follow-up (Fig. 2A). This ﬁnding is consistent with the previ-
ous reports of the BASE ACS trial [11–13]. Nevertheless, these ﬁndings
should be taken with caution, since both the trial population and the
elderly subgroup were underpowered to detect a difference in a rare
event such as deﬁnite ST, and therefore, this ﬁnding might be due to
type I error. It is noteworthy that stent type was not a predictor of
MACE or cardiac death in the elderly subgroup.
4.3. Limitations of the study
The BASE ACS trial was not designed a priori to explore speciﬁc dif-
ferences in outcome based on age. Due to the retrospective nature of
this post hoc analysis, some data relevant to the outcome might have
been missed. In addition, the trial may be underpowered for speciﬁcsubgroup analysis; therefore, we cannot rule out a type II error as the
cause for failure to demonstrate signiﬁcant difference between the sub-
groups, or between the study stents in either subgroup.Moreover, anal-
ysis of patient data in one subgroup with different stent designs should
also be interpreted with caution. Finally, the current post hoc analysis
was a non-randomized subgroup analysis; this might limit the conclu-
siveness of the results.
5. Conclusion
Elderly patients presenting with ACS who were treated with early
PCI had worse long-term clinical outcome, compared with younger
ones, mainly due to a higher death rate. The long-term outcome of
BASwas comparable to that of EES in the elderly, as well as in the youn-
ger subgroup.
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